COPENHAGEN, April 8 (Reuters) - The Novo Nordisk Foundation has refiled an application to the U.S. Federal Trade Commission for approval of a $16.5 billion deal to buy Catalent, a spokesperson said on Monday. (Reporting by Jacob Gronholt-Pedersen, writing by Stine Jacobsen, editing by Anna Ringstrom)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
927.3 DKK | +1.13% | -0.16% | +32.83% |
May. 31 | Zealand Pharma Secures EU Panel Backing for Severe Hypoglycemia Treatment | MT |
May. 30 | Danish Government Implements Stricter Subsidy Rules for Diabetes Drugs | MT |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
927.3 DKK | +1.13% | -0.16% | 598B | ||
53.79 USD | +0.34% | -1.88% | 9.73B | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+32.83% | 598B | |
+40.73% | 739B | |
-6.30% | 353B | |
+15.15% | 318B | |
+4.05% | 285B | |
+15.00% | 240B | |
-5.52% | 206B | |
+6.17% | 164B | |
-0.45% | 162B | |
-.--% | 122B |
- Stock Market
- Equities
- NOVO B Stock
- News Novo Nordisk A/S
- Novo Nordisk owner refiles U.S. application for approval of Catalent deal